Hexagon Nutrition IPO: Check IPO Date, Live Subscription and Key Details
Hexagon Nutrition Limited, incorporated in 1993, is a research-focused clinical nutrition and food-science enterprise. The company is engaged in the development, manufacturing, and marketing of high-value micronutrient premixes, branded clinical nutrition wellness lines, therapeutic formulations, and ready-to-use nutritional foods (RUFs). Hexagon operates three advanced industrial manufacturing hubs in India (Nasik, Chennai, and Thoothukudi) along with an international factory setup in Tashkent, Uzbekistan. Its Chennai and Thoothukudi facilities are strategically positioned within Special Economic Zones (SEZs) to optimize export logistics and secure duty-free raw material imports.
Price Range
₹42.0 - ₹45.0
Issue Size
₹138.87 Cr
Lot Size
333 shares
IPO Type
Mainboard
GMP
-
Est. Listing Price
₹45
Estimate Profit
-
Retail Portion
35.00%
Key Metrics
Check Live GMPGMPFace Value
₹1
EPS
2.93
P/E Ratio
15.35
RoNW
12.46%
ROE
13.02%
Debt to Equity
0.18
Advertisement
Timeline
IPO Opens
5 Jun
IPO Closes
9 Jun
Allotment
10 Jun
Listing
12 Jun
IPO Timeline & Listing Details
| Event | Date | Details |
|---|---|---|
| IPO Open Date | 5 June 2026 | Subscription starts |
| IPO Close Date | 9 June 2026 | Subscription ends |
| Allotment Date | 10 June 2026 | Allotment |
| Listing Date | 12 June 2026 | Listing |
Investment Categories
| Category | Lots | Amount |
|---|---|---|
Retail (Min) | 1 | ₹14,985 |
Retail (Max)Just less than ₹2,00,000 | 13 | ₹1,94,805 |
SHNI (Min)Just above ₹2,00,000 | 14 | ₹2,09,790 |
SHNI (Max)Below ₹10,00,000 | 66 | ₹9,89,010 |
BHNIAbove ₹10,00,000 | 67 | ₹10,03,995 |
IPO Reservation Details
| Category | Reservation |
|---|---|
| QIB (Qualified Institutional Buyer) | 50.00% |
| NII (Non-Institutional Investor) | 15.00% |
| SHNI (Small Non-Institutional Investor) | 5.00% |
| BHNI (Big Non-Institutional Investor) | 10.00% |
| Retail | 35.00% |
| Total | 100.00% |
IPO Objectives
- The IPO is entirely an Offer for Sale (OFS) of 3,08,59,704 equity shares by the existing promoter and investor selling shareholders. The company will not receive any direct capital proceeds from the public issue.
- To achieve the benefits of listing the equity shares on the stock exchanges (BSE and NSE) to enhance brand visibility and provide liquidity to shareholders.
Strengths
- The company has established a Differentiated Research Product Niche, building a strong research-driven portfolio that crosses premium clinical nutrition brands (Pentasure, Obesigo, Pediagold) and specialized institutional micronutrient premixes.
- It benefits from a Strategic Global Manufacturing Moat, operating four advanced production units spread across India and Uzbekistan, including two optimized Indian SEZ nodes that minimize import duty friction.
- The business leverages an Expansive Omnichannel Network, reaching wide consumer demographics via 342 domestic retail distributors alongside pharmacy chains, hospital channels, and proprietary digital storefronts.
- It commands a Deep Global Export Base, successfully scaling its clinical and wellness nutritional distribution corridors across more than 75 international boundaries spanning Europe, Africa, and South America.
- The firm maintains a Healthy Balance Sheet, keeping highly conservative leverage limits with a comfortable debt-to-equity layer tracking at just 0.18 as of late 2025.
Weaknesses
- The public issue is structured as a Pure Offer for Sale (OFS) of ₹138.87 Cr, consisting entirely of shares sold by existing promoters, which yields zero fresh corporate capital infusion to fund internal facility expansions or new asset rollouts.
- The business faces Fragile Global Regulatory Exposure, being subject to strict multi-nation healthcare certifications and rigorous quality verifications where any sudden compliance lapse could severely impact export volumes.
- The issue is met with a Quiet Unofficial Gray Market reception, with early Grey Market Premium (GMP) indicators tracking flat at ₹0, signaling highly cautious or cold retail participant sentiment ahead of the launch window.
Advertisement
Financial Performance
| Period Ended | 31 Dec 2025 (9M) | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets (₹ Cr.) | 327.6 | 261.36 | 250.54 | 288.9 |
| Revenue (₹ Cr.) | 275.57 | 331.29 | 304.62 | 281.65 |
| PAT (₹ Cr.) | 27.03 | 24.38 | 12.21 | 5.82 |
| Net Worth (₹ Cr.) | 223.05 | 195.6 | 176.29 | 163.84 |
Peer Comparison
| Company | P/B Ratio | P/E Ratio | RONW (%) | Net Worth (₹ Cr.) |
|---|---|---|---|---|
| Hexagon Nutrition | 2.48 | 15.35 | 13.02% | 223.05 |
| Nestle India Ltd | 53.2 | 78.39 | 67.85% | 4,010.02 |
| Zydus Wellness Ltd | 2.77 | 81.73 | 3.98% | 5,672.25 |
Subscription Details
No daily bids available.
No subscription statistics available.
Advertisement
Company Details
- Hexagon Nutrition Ltd.
- 404 Global Chamber, Adarsh Nagar Link Road, Andheri (W), Mumbai, Maharashtra, 400053
- +91 22 6213 6710
- cs.hnpl@hexagonnutrition.com
- https://www.hexagonnutrition.com/
Registrar Details
- Kfin Technologies Ltd.
- 04067162222, 04079611000
- hexagon.ipo@kfintech.com
- https://ipostatus.kfintech.com/
Frequently Asked Questions
What does Hexagon Nutrition do?
Hexagon Nutrition is a nutrition and food science company that develops and manufactures micronutrient premixes, clinical nutrition products, health supplements, and therapeutic food products for both businesses and consumers.
What are the IPO dates for Hexagon Nutrition IPO?
The Hexagon Nutrition IPO will open for subscription on June 5, 2026, and close on June 9, 2026.
What is the price band and minimum investment for Hexagon Nutrition IPO?
The IPO price band is fixed at ₹42 to ₹45 per share. Retail investors need to apply for a minimum of 1 lot (333 shares), requiring an investment of ₹14,985 at the upper price band.
What is the Grey Market Premium (GMP) of Hexagon Nutrition IPO today?
As of May 31, 2026, the Grey Market Premium (GMP) of Hexagon Nutrition IPO is ₹0, indicating an expected listing price near ₹45 per share.
Where will Hexagon Nutrition IPO be listed?
Hexagon Nutrition IPO is proposed to be listed on both BSE and NSE, with the tentative listing date set for June 12, 2026.
Loading comments...